Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of October 2021. The report serves as a notification to the market regarding the Company's total voting rights and capital structure as of September 30, 2021, in conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital and voting rights data.
- Issued Share Capital: 5,386,949,889 Ordinary Shares of 25 pence each.
- Treasury Shares: 355,205,950 Ordinary Shares.
- Total Voting Rights: 5,031,743,939.
Material Changes
The filing text does not provide a clear value for material changes versus the prior comparable period. The document reports a static snapshot of share capital as of September 30, 2021, without comparative historical data.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory notification intended to assist shareholders in calculating disclosure thresholds under FCA rules.
Important Facts for Investors
- The total number of voting rights (5,031,743,939) should be used as the denominator for determining notification requirements under FCA Disclosure Guidance and Transparency Rules.
- The reported share capital figures are effective as of September 30, 2021.
- This filing contains no operational or financial performance data.